Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 451

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Open access
Healey, Jeff S., Lopes, Renato D., Granger, Christopher B., Alings, Marco, Rivard, Lena, McIntyre, William F., Atar, Dan, Birnie, David H., Boriani, Giuseppe, Camm, A. John, Conen, David, Erath, Julia W., Gold, Michael R., Hohnloser, Stefan H., Ip, John, Kautzner, Josef, Kutyifa, Valentina, Linde, Cecilia, Mabo, Philippe, Mairesse, Georges, Benezet Mazuecos, Juan, Cosedis Nielsen, Jens, Philippon, Francois, Proietti, Marco, Sticherling, Christian, Wong, Jorge A., Wright, David J., Zarraga, Ignatius G., Coutts, Shelagh B., Kaplan, Andrew, Pombo, Marta, Ayala-Paredes, Felix, Xu, Lizhen, Simek, Kim, Nevills, Sandra, Mian, Rajibul, Connolly, Stuart J.·2024·New England Journal of Medicine

Abstract

BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of stroke by a factor of 2.5; however, treatment with oral anticoagulation is of uncertain benefit. METHODS: We conducted a trial involving patients with subclinical atrial fibrillation lasting 6 minutes to 24 hours. Patients were randomly assigned in a double-blind, double-dummy design to receive apixaban at a dose of 5 mg twice daily (2.5 mg twice daily when indicated) or aspirin at a dose of 81 mg daily. The trial medication was discontinued and anticoagulation started if subclinical atrial fibrillation lasting more than 24 hours or clinical atrial fibrillation developed. The primary efficacy outcome, stroke or systemic embolism, was assessed in the intention-to-treat population (all the patients who had undergone randomization); the primary safety outcome, major bleeding, was assessed in the on-treatment population (all the patients who had undergone randomization and received at least one dose of the assigned trial drug, with follow-up censored 5 days after permanent discontinuation of trial medication for any reason). RESULTS: -VASc score of 3.9±1.1 (scores range from 0 to 9, with higher scores indicating a higher risk of stroke); 36.1% of the patients were women. After a mean follow-up of 3.5±1.8 years, stroke or systemic embolism occurred in 55 patients in the apixaban group (0.78% per patient-year) and in 86 patients in the aspirin group (1.24% per patient-year) (hazard ratio, 0.63; 95% confidence interval [CI], 0.45 to 0.88; P = 0.007). In the on-treatment population, the rate of major bleeding was 1.71% per patient-year in the apixaban group and 0.94% per patient-year in the aspirin group (hazard ratio, 1.80; 95% CI, 1.26 to 2.57; P = 0.001). Fatal bleeding occurred in 5 patients in the apixaban group and 8 patients in the aspirin group. CONCLUSIONS: Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2310234

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 451

Metadata

Authors
Healey, J. S., Lopes, R. D., Granger, C. B., Alings, M., Rivard, L., McIntyre, W. F., Atar, D., Birnie, D. H., Boriani, G., Camm, A. J., Conen, D., Erath, J. W., Gold, M. R., Hohnloser, S. H., Ip, J., Kautzner, J., Kutyifa, V., Linde, C., Mabo, P., Mairesse, G., Benezet Mazuecos, J., Cosedis Nielsen, J., Philippon, F., Proietti, M., Sticherling, C., Wong, J. A., Wright, D. J., Zarraga, I. G., Coutts, S. B., Kaplan, A., Pombo, M., Ayala-Paredes, F., Xu, L., Simek, K., Nevills, S., Mian, R., & Connolly, S. J.
Venue
New England Journal of Medicine
Published
2024-01-11
Volume
390
Issue
2
Pages
107-117
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4388609933
Cited by
451
References
27
FWCI
79.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. https://app.cochat.ai/papers/10.1056/nejmoa2310234
The paper
Healey, J. S., Lopes, R. D., Granger, C. B., Alings, M., Rivard, L., McIntyre, W. F., Atar, D., Birnie, D. H., Boriani, G., Camm, A. J., Conen, D., Erath, J. W., Gold, M. R., Hohnloser, S. H., Ip, J., Kautzner, J., Kutyifa, V., Linde, C., Mabo, P., . . . Connolly, S. J. (2024). Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2310234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.